Clearmind Strengthens its Scientific Advisory Board With Substance Abuse and Mental Health Professionals
May 09, 2022 09:30 ET
|
Clearmind Medicine Inc.
Prof. Schütz’ main research interests focus on clinical interventions and health service in substance use disorders and mental health diagnoses; Prof. Weiser specializes in psychiatric disorders such...
Clearmind Medicine to Partner with Microdose for Psychedelic Capital: Mar 2022 Today, Thursday, March 24th
March 24, 2022 15:00 ET
|
Clearmind Medicine Inc.
TORONTO, March 24, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the...
Clearmind Medicine Announces Positive Results on CMND-100 trials
March 17, 2022 08:00 ET
|
Clearmind Medicine Inc.
Two pre-clinical trials based on MEAI exhibited a significant suppressive effect on alcohol consumption in mice TORONTO, March 17, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND,...
Clearmind Medicine, SciSparc Launch a Psychedelic Pharma Collaboration
March 08, 2022 08:30 ET
|
Clearmind Medicine Inc.
The companies have begun the Collaboration with a joint pre-clinical study and are expecting its results potentially to deepen the Collaboration between the parties. TORONTO, March 08, 2022 (GLOBE...
Clearmind Medicine Partners with Dr. Gabor Maté to Discuss Alcohol Use Disorder and Trauma in a Special Virtual Event on February 3
January 28, 2022 09:00 ET
|
Clearmind Medicine Inc.
A renowned speaker, and bestselling author, Dr. Gabor Maté is highly sought after for his expertise on a range of topics including addiction, stress and childhood development TORONTO, Jan. 28, 2022 ...
Clearmind Medicine to Host ‘Psychedelics for Alcoholism‘ Virtual Educational Event on October 20
October 01, 2021 08:00 ET
|
Clearmind Medicine
TORONTO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and...
Mark Haden, Psychedelic Medicine Expert, Joins Clearmind Medicine’s Advisory Board
August 03, 2021 07:00 ET
|
Clearmind Medicine
Toronto, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of...
Clearmind Issues Shareholder Letter
July 20, 2021 07:00 ET
|
Clearmind Medicine
Toronto, July 20, 2021 (GLOBE NEWSWIRE) -- via InvestorWire-- Clearmind Medicine Inc. (CSE: CMND) ("Clearmind" or the "Company"), a psychedelic medicine biotech company focused on the discovery and...